Table 1.

ABCB1 SNPs demonstrate significant association with clinical outcome in patients enrolled in GO arm of the randomized AAML0531 clinical trial

ABCB1 SNPs	Differences by ABCB1 genotypes within No-GO or GO arm
ABCB1 SNP_rs1045642	No-GO ARM (rs1045642)					GO-ARM (rs1045642)
	% ± 2SE%	% ± 2SE%	% ± 2SE%	p	p	% ± 2SE%	% ± 2SE%	% ± 2SE%	p	p
	CC (N = 132)	CT (N = 244)	TT (N = 93)	CC vs. CT vs. TT	CC vs. CT+TT	CC (N = 128)	CT (N = 238)	TT (N = 102)	CC vs. CT vs. TT	CC vs. CT+TT
5 years OS	63 ± 9%	62 ± 6%	70 ± 10%	0.323	0.371	59 ± 9%	66 ± 7%	71 ± 10%	0.123	0.068
5 years EFS	50 ± 9%	44 ± 6%	48 ± 11%	0.633	0.466	44 ± 9%	55 ± 7%	56 ± 10%	0.073	0.022
	CC (N = 91)	CT (N = 171)	TT (N = 64)	CC vs. CT vs. TT	CC vs. CT+TT	CC (N = 97)	CT (N = 182)	TT (N = 77)	CC vs. CT vs. TT	CC vs. CT+TT
5 years DFS from EOC1	56 ± 11%	50 ± 8%	55 ± 13%	0.441	0.472	51 ± 10%	62 ± 7%	64 ± 11%	0.126	0.044
5 years RR from EOC1	40 ± 11%	47 ± 8%	43 ± 13%	0.378	0.278	45 ± 10%	30 ± 7%	28 ± 10%	0.024	0.007

ABCB1 SNP_rs2235015	No-GO ARM (rs2235015)					GO ARM (rs2235015)
	% ± 2SE%	% ± 2SE%	% ± 2SE%	p	p	% ± 2SE%	% ± 2SE%	% ± 2SE%	p	p
	GG (N = 300)	GT (N = 141)	TT (N = 24)	GG vs. GT vs. TT	GG+GT vs. TT	GG (N = 295)	GT (N = 141)	TT (N = 27)	GG vs. GT vs. TT	GG+GT vs. TT
5 years OS	64 ± 6%	63 ± 8%	66 ± 20%	0.848	0.954	65 ± 6%	68 ± 8%	54 ± 20%	0.450	0.247
5 years EFS	46 ± 6%	49 ± 9%	41 ± 20%	0.892	0.644	52 ± 6%	55 ± 8%	37 ± 19%	0.303	0.156
	GG (N = 212)	GT (N = 94)	TT (N = 16)	GG vs. GT vs. TT	GG+GT vs. TT	GG (N = 219)	GT (N = 111)	TT (N = 22)	GG vs. GT vs. TT	GG+GT vs. TT
5 years DFS from EOC1	52 ± 7%	55 ± 10%	49 ± 26%	0.934	0.719	60 ± 7%	60 ± 9%	41 ± 21%	0.286	0.118
5 years RR from EOC1	46 ± 7%	40 ± 10%	45 ± 27%	0.851	0.929	33 ± 7%	30 ± 9%	59 ± 22%	0.046	0.016

The bold values indicate statistically significant p value of <0.05